Answers are grounded in this paper and cite their sources.
Elderly patients receiving bevacizumab with first-line chemotherapy showed treatment benefit, although there was reduced median survival with increasing age. There was no increased toxicity among elderly patients, except for risk of ATEs.
No takes yet. Share an insight, caveat, or question.
Kozloff et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: